Name: utilizing functional genomics screening to identify potentially novel drug targets in cancer cell spheroid cultures
Uploaded: 2016-12-26T12:00:00.000+00:00
Duration: 7 min 48 s
Description: Watch this Scientific Journal Video about Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures at JoVE.com

The authors would like to thank Fredrik Walberg (FACS and imaging facility, ICR) for assistance with microscopy. This work was funded by Breast Cancer Now. RN is the recipient of a Breast Cancer Now Career Development Fellowship (2011MaySF01).

1. Preparation of 96-well siRNA Plates
NOTE: The outer edges of a 96-well plate are more prone to evaporation compared to other wells, thus limit the amount of siRNAs to 60 per 96-well plate. Fill in outer wells with plain medium or PBS to limit this. In addition, a validation screen of hits is recommended to alleviate plate biases.
<ol>
	<li>Dilute the siRNAs to 250 - 500 ng/&#956;L in reduced serum medium (as per manufacturer&#39;s recommendations) and aliquot 10 &#956;L to the appropriate wells of the ultra-low attachment plate. Perform all screens in triplicate. 
	NOTE: Incorporate appropriate non-targeting (negative) and killing (positive, such as UBB and PLK1) siRNA controls in the plate design to ensure transfection efficiency can be assessed. The use of low-attachment plates for the siRNA work is critical, as cells will be added to the transfection mixture. We cannot rule out that some manufacturers ultra-low attachment plates may have subtle effects on spheroid growth. As such we recommend that these are tested by the end user.</li>
	<li>Cover plates with adhesive seals and store at -20 &#176;C.</li>
</ol>
2. Reverse Transfection of Cell Line
<ol>
	<li>On the day of the screen, defrost the plates at room temperature and spin for 5 min at 1,000 x g using a bench-top centrifuge. Add 10 &#956;L of reduced serum medium containing the optimized-transfection reagent to each well using a multichannel pipette. Leave plates for 15 min for transfection complexes containing siRNA to form. 
	NOTE: This study utilized the breast cancer cell line BT474 for functional genomic screening (cultured in high glucose DMEM (Dulbecco&#39;s Modified Eagle Medium) supplemented with 10% fetal bovine serum (FBS) and antibiotics).</li>
	<li>Trypsinize the cells to be screened (0.05% trypsin and 0.53 mM EDTA) until they detach from the flask, neutralize using appropriate volume of cell line specific medium and spin for 5 min at 1,000 x g on a bench-top centrifuge to remove trypsin. Resuspend cells with an appropriate volume of medium and determine accurate cell number using a cell counter. 
	NOTE: Typically 5,000 cells per well are sufficient for spheroid formation across most cell lines tested. It is important to accurately count the cells as a single cell suspension for accurate size comparisons.</li>
	<li>Dilute cells to 5,000 cells per 180 &#956;L in cold medium (4 &#176;C). 
	NOTE: The addition of reconstituted basement membrane matrix components will negatively impact transfection efficiency and it is recommended that it is not used. Cell line optimization to confirm spheroid forming capacity and knockdown efficacy should be performed prior to the screen.</li>
	<li>Transfer the cell suspension to a reservoir, pipet to mix and add 180 &#181;L to each well of the 96-well ultra-low attachment plate containing the siRNA prepared previously (2.1).</li>
	<li>Centrifuge the plate at 1,000 x g in a precooled 4 &#176;C centrifuge for 10 min and then return to a 37 &#176;C tissue culture incubator.</li>
	<li>NOTE: The cells will appear as a mosaic in the bottom of the wells. Over the next 12 - 24 h the cells will aggregate together to form a single sphere.</li>
	<li>After 24 h, observe the cells form a single spheroid in the center of the well. Add 100 &#181;L of complete medium to each well to encourage growth.</li>
	<li>Replenish medium after three days. Gently remove 100 &#181;L of medium from each well and add 100 &#181;L of fresh medium.</li>
	<li>On day 7, quantify the automated spheroid size on a plate reader that can quantitatively monitor spheroid growth over time (see Section 3).</li>
	<li>Afterwards, determine cell viability using a luminescent cell viability dye (see Section 4).</li>
</ol>
3. Automated Image Acquisition
<ol>
	<li>Scan the plates on a bench-top, micro-well plate imaging cytometer on day 7.
	<ol>
		<li>Open the software, select the following: &#39;96-well plate&#39;, select the appropriate plate type and enter an experiment name. NOTE: Any additional information can also be added into the software.</li>
		<li>Select the &#39;Tumorsphere&#39; application. Alter the focus so that the spheroid is in focus and has optimal contrast. 
		NOTE: We recommend &#39;image based focus&#39; as significant variations in spheroid sizes are expected.</li>
		<li>Select the wells that require scanning and &#39;Start scan&#39;.</li>
		<li>Using the plate scanner software, ensure that the object mask accurately represents the spheroid size. Do this by adjusting the colony diameter, border dilation, minimum thickness and precision settings, specific to each cell line tested 11,12. 
		NOTE: The spheroid area will then be calculated using the software algorithm. For example, to accurately calculate the area of BT474 spheroids grown for seven days adjust precision to &#39;high&#39; and set the minimum colony diameter to 200 &#181;M. This should produce an appropriate spheroid mask representative of the spheroid area. 
		NOTE: These data can then be exported from the machine, using the export function, in in the form of an annotated data file. Date is plate median normalized, combined and analyzed either by z-score or strictly standardized mean difference (SSMD) to identify siRNAs that had a statistically significant effect on spheroid area.</li>
	</ol>
	</li>
</ol>
4. Determining Cell Viability
<ol>
	<li>After spheroid area has been calculated, determine the viability using a luminescent viability cell dye. Prepare the reagent as per the manufacturer&#39;s instructions.</li>
	<li>Carefully remove 100 &#181;L of medium from each well and add 100 &#181;L of viability dye. Incubate plates for 15 min then scan using a luminescent plate reader. 
	NOTE: These data can then be exported from the machine, using the export function, in in the form of an annotated data file. Date is plate median normalized, combined and analyzed either by z-score or strictly standardized mean difference (SSMD) to identify siRNAs that had a statistically significant effect on spheroid viability.</li>
</ol>

<ol>
	<li>Seton-Rogers, S. E., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Cooperation+of+the+ErbB2+receptor+and+transforming+growth+factor+beta+in+induction+of+migration+and+invasion+in+mammary+epithelial+cells.">Cooperation of the ErbB2 receptor and transforming growth factor beta in induction of migration and invasion in mammary epithelial cells.</a> Proc Natl Acad Sci U S A. 101 (5), 1257-1262 (2004).</li><li>Debnath, J., Muthuswamy, S. K., Brugge, J. S. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Morphogenesis+and+oncogenesis+of+MCF-10A+mammary+epithelial+acini+grown+in+three-dimensional+basement+membrane+cultures.">Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures.</a> Methods. 30 (3), 256-268 (2003).</li><li>Chia, S. K., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Prognostic+significance+of+a+novel+hypoxia-regulated+marker,+carbonic+anhydrase+IX,+in+invasive+breast+carcinoma.">Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma.</a> J Clin Oncol. 19 (16), 3660-3668 (2001).</li><li>Trastour, C., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=HIF-1alpha+and+CA+IX+staining+in+invasive+breast+carcinomas:+prognosis+and+treatment+outcome.">HIF-1alpha and CA IX staining in invasive breast carcinomas: prognosis and treatment outcome.</a> Int J Cancer. 120 (7), 1451-1458 (2007).</li><li>Wilson, W. R., Hay, M. P. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Targeting+hypoxia+in+cancer+therapy.">Targeting hypoxia in cancer therapy.</a> Nat Rev Cancer. 11 (6), 393-410 (2011).</li><li>Ros, S., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Functional+metabolic+screen+identifies+6-phosphofructo-2-kinase/fructose-2,6-biphosphatase+4+as+an+important+regulator+of+prostate+cancer+cell+survival.">Functional metabolic screen identifies 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4 as an important regulator of prostate cancer cell survival.</a> Cancer Discov. 2 (4), 328-343 (2012).</li><li>Baenke, F., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Functional+screening+identifies+MCT4+as+a+key+regulator+of+breast+cancer+cell+metabolism+and+survival.">Functional screening identifies MCT4 as a key regulator of breast cancer cell metabolism and survival.</a> J Pathol. 237 (2), 152-165 (2015).</li><li>Schug, Z. T., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Acetyl-CoA+synthetase+2+promotes+acetate+utilization+and+maintains+cancer+cell+growth+under+metabolic+stress.">Acetyl-CoA synthetase 2 promotes acetate utilization and maintains cancer cell growth under metabolic stress.</a> Cancer Cell. 27 (1), 57-71 (2015).</li><li>Mashimo, T., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Acetate+is+a+bioenergetic+substrate+for+human+glioblastoma+and+brain+metastases.">Acetate is a bioenergetic substrate for human glioblastoma and brain metastases.</a> Cell. 159 (7), 1603-1614 (2014).</li><li>Comerford, S. A., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Acetate+dependence+of+tumors.">Acetate dependence of tumors.</a> Cell. 159 (7), 1591-1602 (2014).</li><li>Vinci, M., Box, C., Eccles, S. A. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Three-dimensional+(3D)+tumor+spheroid+invasion+assay.">Three-dimensional (3D) tumor spheroid invasion assay.</a> J Vis Exp. (99), e52686 (2015).</li><li>Vinci, M., Box, C., Zimmermann, M., Eccles, S. A. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Tumor+spheroid-based+migration+assays+for+evaluation+of+therapeutic+agents.">Tumor spheroid-based migration assays for evaluation of therapeutic agents.</a> Methods Mol Biol. 986, 253-266 (2013).</li><li>Barretina, J., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=The+Cancer+Cell+Line+Encyclopedia+enables+predictive+modelling+of+anticancer+drug+sensitivity.">The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.</a> Nature. 483 (7391), 603-607 (2012).</li><li>Maguire, S. L., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=SF3B1+mutations+constitute+a+novel+therapeutic+target+in+breast+cancer.">SF3B1 mutations constitute a novel therapeutic target in breast cancer.</a> J Pathol. 235 (4), 571-580 (2015).</li><li>Brough, R., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Functional+viability+profiles+of+breast+cancer.">Functional viability profiles of breast cancer.</a> Cancer Discov. 1 (3), 260-273 (2011).</li><li>Ferber, E. C., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=FOXO3a+regulates+reactive+oxygen+metabolism+by+inhibiting+mitochondrial+gene+expression.">FOXO3a regulates reactive oxygen metabolism by inhibiting mitochondrial gene expression.</a> Cell Death Differ. 19 (6), 968-979 (2012).</li><li>Jensen, K. S., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=FoxO3A+promotes+metabolic+adaptation+to+hypoxia+by+antagonizing+Myc+function.">FoxO3A promotes metabolic adaptation to hypoxia by antagonizing Myc function.</a> EMBO J. 30 (22), 4554-4570 (2011).</li><li>Ivascu, A., Kubbies, M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Diversity+of+cell-mediated+adhesions+in+breast+cancer+spheroids.">Diversity of cell-mediated adhesions in breast cancer spheroids.</a> Int J Oncol. 31 (6), 1403-1413 (2007).</li><li>Bitler, B. G., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Synthetic+lethality+by+targeting+EZH2+methyltransferase+activity+in+ARID1A-mutated+cancers.">Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers.</a> Nat Med. 21 (3), 231-238 (2015).</li><li>Dow, L. E., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Inducible+in+vivo+genome+editing+with+CRISPR-Cas9.">Inducible in vivo genome editing with CRISPR-Cas9.</a> Nat Biotechnol. 33 (4), 390-394 (2015).</li></ol>

Open Access fees were supported by Nexcelom Bioscience, LLC.

Three-dimensional models of cancer are being increasingly employed to evaluate the efficacy of known and novel compounds that have been designed to selectively kill cancer cells. Cancer cell spheroids are structures that display conditions more similar to those encountered in tumors in vivo, thus compounds that have increased efficacy in 3D are more likely to have an effect in vivo. However, these modalities do not allow for the identification of potentially novel targets that have not been the subject of drug design that could have considerable efficacy in treating cancer.
We developed a siRNA functional genomics approach that allowed for durable gene silencing for up to seven days in cancer cell line spheroids. There are several critical steps to the protocol that require optimization before a siRNA screen can be performed. The ability to form reproducible viable spheroids on a large scale is essential. Moreover, appropriate transfection conditions should be rigorously optimized. We suggest trialing several different transfection reagents with appropriate non-targeting and killing controls prior to attempting the screen. We were able to show that several commonly used breast cancer cell lines, namely BT474, MCF10DCIS.com, MDA-MB-231 and JIMT1 were amenable to siRNA transfection. Furthermore, we provide proof-of-principle data screening the 200 most frequently mutated genes in breast cancer in BT474 spheroids, confirmed their dependency on amplification of HER2 and oncogenic mutation of PIK3CA. Interestingly, silencing of the transcription factor FOXO3 resulted in a reduction in spheroid size but no significant effect on viability. FOXO3 is known to regulate the response to hypoxia, altering the metabolic capacity of cancer cells allowing them to adapt more readily to their environment 16. This role could potentially interfere with the cell viability reading as it detects ATP abundance, one of the main products of cell metabolism.
In support of the observation of a reduction in spheroid size, it has been shown that silencing of FOXO3 in HeLa xenografts impaired tumor growth and induced apoptosis 17. It is important to note that some genes may impact the capacity of cancer cells to retain their 3D architecture, which could result in false positives. For example, knockdown of E-Cadherin resulted in dissolution of BT474 spheroid structure. This had been previously reported using E-Cadherin targeted antibodies 18. As with any screening platform, potential targets should be rescreened to assess the reproducibility of the effect observed. There are limitations to the technique, namely the transient nature of the siRNA-mediated gene knockdown. Sustained silencing longer than seven days was not achievable with siRNA.
The advantage of this approach is that it can be coupled with various other biometric dyes not just those that assess spheroid viability, for example, giving spatial information of spheroid hypoxia or monitoring cells undergoing apoptosis. Moreover, because the plate reader scans are relatively quick and non-invasive, the impact of siRNAs on spheroid size can be assessed over time rather than just at the experimental end point. Indeed, we are currently exploring several of these avenues within our screening pipeline. An alternative approach that utilizes 3D cultures to identify novel dependencies is the use of chemical libraries that inhibit either a broad range of targets or particular families of proteins. Indeed, Bitler et al. utilized this targeted approach to identify the synthetic lethality interaction between ARID1A status and EZH2 inhibitors in ovarian clear cell carcinomas 19. The discovery of CRISPR-Cas9 gene editing technology has also allowed for the development of genetic screens in organoid cultures and in vivo. However, this approach is dependent on having appropriate animal facilities and may be cost prohibitive 20.
In conclusion, we believe that we have outlined a protocol that more accurately models the oxygen and nutrient gradients, which are features of the tumor microenvironment in vivo, allowing for the identification of novel cancer targets or robust validation of established targets. Moreover, our protocol can be applied to any type of cell line that forms spheroids and hence can be routinely used in the cancer research community for high-throughput siRNA screens.

Solid tumors display significant histological, genetic and micro-environmental intra-tumor heterogeneity, which presents clinicians with a significant challenge in being able to treat patients successfully. The majority of models used to identify novel targeted therapies do not incorporate many of these features. Indeed, current targeted therapies utilized in the clinic have been developed in the last decade employing screening approaches that rely on cancer cell lines grown under two-dimensional (2D) culture conditions. Although this has brought about various successes, such as receptor tyrosine kinase inhibitors, it is becoming apparent that more complex models of cancer are required to fully appreciate the contributing factors that drive tumorigenesis in vivo and increase the number of new therapies that make the transition from pre-clinical models to clinical trials. Moreover, it is now well appreciated that 2D culture systems fail to reflect in vivo behavior 1,2. For example, in poorly vascularized tumors, as the demand for oxygen and nutrients within the microenvironment outstrip supply, regions of high and low deliveries develop. The presence of low oxygen (hypoxia) in tumors, as detected by the immunohistochemical staining of tumor sections for established hypoxic markers such as carbonic anhydrase IX (CAIX), correlates with a poorer clinical outcome in breast cancer 3,4 Thus incorporating features such as hypoxia into screening models may enhance our capacity to discover novel drug targets that will be more efficacious in vivo. Indeed, successfully targeting aggressive tumors that contain hypoxia is a clinical priority 5.
The altering of traditional 2D siRNA screening, in an attempt to more accurately recapitulate elements of the conditions encountered by cancer cells in the tumor microenvironment, has led to the identification of several genes that have been found to be important for tumor growth in vivo. These include functional genomic screens performed under low serum conditions 6, hypoxic conditions 7 and in combination 8. For example, silencing of 6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase 4 (PFKFB4), a protein responsible for regulating carbon entering glycolysis, only induced apoptosis in prostate cancer lines derived from metastasis when grown in low serum. Silencing of PFKFB4 in normal prostate cell lines under the same conditions had no effect, whereas, depletion of PFKFB4 completely ablated the growth of prostate cancer cell line xenografts 6.
In an extended panel of breast cancer cell lines, the silencing of mono-carboxylase transporter 4 (MCT4) preferentially led to the reduction of cell line growth under conditions of low oxygen. This vulnerability was validated in vivo in breast cancer cell line orthotropic xenografts. Perhaps most strikingly, silencing of Acetyl-CoA synthetase 2 (ACSS2), an enzyme responsible for converting acetate into acetyl-CoA, reduced cancer cell number under nutrient stress conditions (low oxygen and serum) but had little or no effect under normal culture conditions 8. Ablation of ACSS2 impacted the growth of breast and prostate cancer xenografts suggesting that nutrient gradients do not exist in isolation within the tumor microenvironment and that cells that reside in these regions are essential for tumor progression 8. Furthermore, ACSS2 was also found to be important in glioblastoma and hepatocellular carcinomas 9,10, suggesting that increased ACSS2 activity in tumors could be a fundamental mechanism that supports growth under unfavorable conditions.
Collectively, these studies prove that recapitulating the conditions encountered in vivo and performing siRNA screens allows for the identification of genes essential for cancer survival. As well as impacting 2D cancer cell growth under nutrient stress conditions, depletion of target genes in these studies inhibited cancer cell line spheroid growth, mirroring what was observed in tumor xenografts 6,8. Thus, cancer cell line spheroids contain several of the conditions encountered in the tumor microenvironment that impart sensitivity to ACSS2 silencing. Indeed, spheroids display nutrient gradients (Serum and oxygen), changes in pH, three-dimensional (3D) cell-cell contact, but also, alterations in proliferative celerity with cells undergoing cell cycle arrest and apoptosis. This is exemplified by the presence in cancer spheroids of necrotic regions, a feature not found in traditional 2D culture.
Cancer cell spheroids have already been used as more biologically relevant models to screen small molecule inhibitors but this only allows for the validation of compound efficacy or the repurposing of compounds originally design for other diseases 11. Current spheroid screening methods do not allow for the analysis of specific gene depletion in a high-throughput of high-content manner. Here, we describe for the first time, a functional genomics pipeline for uncovering specific gene dependencies utilizing small interfering RNA (siRNA) technology in cancer cell line spheroids. We designed a bespoke library with siRNAs targeting the 200 most frequently mutated genes in human breast cancers and assessed the impact of gene depletion on spheroid size and metabolic activity in BT474 breast cancer spheroids. We were able to robustly and reproducibly detect the impact of ERBB2 and PIK3CA silencing in 3D cultures. Moreover, we could assess the impact of gene depletion on the spatial architecture of BT474 spheroids using immunohistochemistry.

<table><tbody><tr><td>Lullaby</td><td>Oz Biosciences</td><td>LL70500&amp;nbsp;</td><td>lipid-based transfection reagent</td></tr><tr><td>Viromer</td><td>Lipocalyx</td><td>VB-01LB-01</td><td>virus-like polymer transfection reagent</td></tr><tr><td>Ultra-low attachment plate</td><td>Corning</td><td>CLS7007</td><td>96 well plate</td></tr><tr><td>Foil plate seals</td><td>ThermoFisher</td><td>AB-0626</td><td></td></tr><tr><td>Luminescent cell viability dye</td><td>Promega</td><td>G7570</td><td>CellTitre-Glo</td></tr><tr><td>Pipette tips (200 &amp;#956;L)</td><td>Starlab</td><td>S1111-0806</td><td></td></tr><tr><td>Pipette tips (10 &amp;#956;L)</td><td>Starlab</td><td>S1111-3800</td><td></td></tr><tr><td>Pipette tips (1, 000 &amp;#956;L)</td><td>Starlab</td><td>S1122-1830</td><td></td></tr><tr><td>Serological pipettes (5 mL)</td><td>Sarstedt</td><td>86.1253.025</td><td></td></tr><tr><td>Serological pipettes (10 mL)</td><td>Sarstedt</td><td>86.1254.025</td><td></td></tr><tr><td>Serological pipettes (25 mL)</td><td>Sarstedt</td><td>86.1685.020</td><td></td></tr><tr><td>RPMI Media</td><td>GIBCO</td><td>11875-093</td><td></td></tr><tr><td>DMEM Media</td><td>GIBCO</td><td>11965-084</td><td></td></tr><tr><td>Opti-MEM</td><td>GIBCO</td><td>31985070</td><td></td></tr><tr><td>Feta bovine serum</td><td>GIBCO</td><td>16140063</td><td></td></tr><tr><td>siRNA</td><td>Dharmacon</td><td>Cherry picked library</td><td></td></tr><tr><td>Countess Cell Counter</td><td>ThermoFisher Scientific</td><td>AMQAX1000</td><td></td></tr><tr><td>Cell counting chamber slides</td><td>ThermoFisher Scientific</td><td>C10312</td><td></td></tr><tr><td>Celigo S</td><td>Nexcelom</td><td>contact company</td><td></td></tr><tr><td>Victor X5</td><td>Perkin Elmer</td><td>contact company</td><td></td></tr><tr><td>Benchtop centrifuge</td><td>Various</td><td></td><td></td></tr><tr><td>Axiovert Inverted brightfield microscope</td><td>Zeiss</td><td>contact company</td><td></td></tr><tr><td>Tissue culture CO&lt;sub&gt;2&lt;/sub&gt;; Incubator</td><td>Various</td><td></td><td></td></tr><tr><td>Mulitichannel pipette</td><td>Various</td><td></td><td></td></tr></tbody></table>

utilizing functional genomics screening to identify potentially novel drug targets in cancer cell spheroid cultures

The identification of functional driver events in cancer is central to furthering our understanding of cancer biology and indispensable for the discovery of the next generation of novel drug targets. It is becoming apparent that more complex models of cancer are required to fully appreciate the contributing factors that drive tumorigenesis in vivo and increase the efficacy of novel therapies that make the transition from pre-clinical models to clinical trials.
Here we present a methodology for generating uniform and reproducible tumor spheroids that can be subjected to siRNA functional screening. These spheroids display many characteristics that are found in solid tumors that are not present in traditional two-dimension culture. We show that several commonly used breast cancer cell lines are amenable to this protocol. Furthermore, we provide proof-of-principle data utilizing the breast cancer cell line BT474, confirming their dependency on amplification of the epidermal growth factor receptor HER2 and mutation of phosphatidylinositol-4,5-biphosphate 3-kinase (PIK3CA) when grown as tumor spheroids. Finally, we are able to further investigate and confirm the spatial impact of these dependencies using immunohistochemistry.

Spheroid assays in ultra-low attachment 96-well plates provide a high-throughput phenotypic assessment for potential oncogenicity in a context that more readily recapitulates the physiological conditions found in tumors in vivo. Indeed, the cancer cell lines MCF10DCIS.com and BT474 form tight spheroid structures (Figure 1A) and immunohistological investigation of spheroid sections showed distinct spatial changes in cellular and nuclear morphology. Over time, some spheroids such as BT474 spheroids develop necrotic regions, a common feature of aggressive solid tumors (Figure 1B). Some spheroids do not develop necrotic cores, such as the MDA-MB-231 cell line, but do display marked variation in the proliferative marker Ki67, which inversely correlates with cleaved caspsase-3 expression, a marker of apoptosis (Figure 1C). To establish that multiple cell lines are indeed receptive to siRNA-mediated gene silencing BT474, MCF10DCIS.com, MDA-MB-231 and JIMT1 cells were reverse transfected with siRNA for seven days. The presence of transfection reagent (mock) or transfection of control siRNAs had no effect on spheroid viability, while silencing of the essential gene Ubiquitin B (UBB) significantly reduced spheroid viability in all the cell lines tested (Figure 1D).
We designed a human siRNA library that encompassed the most frequently mutated genes in unselected, ER+, HER2+ and triple negative breast cancers. This library consists of genes of known function, such as MYC, PIK3CA and TP53 and those whose contribution to carcinogenesis is not established. The screen also contains several non-targeting control siRNAs (Control #1, Control #2) and siRNAs targeting essential genes, such as PLK1 and UBB, which act as killing controls (Table 1). We chose to use the breast cancer cell lines BT474 as they readily form spheroids without the addition of reconstituted basement membrane, are established workhorse cell lines and have a known genomic architecture. For example, BT474 cells are positive for the estrogen receptor (ER+), overexpress the human epidermal growth factor receptor 2 (HER2+) and harbor mutations in TP53 (E285K) and PIK3CA (K111N)13.
Employing the protocol outlined above, we monitored the impact gene depletion had on spheroid size and viability after seven days of siRNA reverse transfection (Figure 1E). Interestingly, the majority of genes did not have a significant effect on spheroid area or viability (Figure 2A). Silencing of FOXO3, PIK3CA, ERBB2 and SF3B1 resulted in the most significant reproducible reduction in spheroid size. This reduction was also observed in spheroid viability after ERBB2 and SF3B1 silencing. Encouragingly, we confirmed the impact of PIK3CA, ERBB2 and SF3B1 silencing on spheroid size using bright-field microscopy (Figure 2B). We previously identified SF3B1 as an essential gene in numerous cell line models and thus siSF3B1 represents a good killing control in addition to UBB 14. Interestingly, of all 200 genes only the silencing of E-Cadherin resulted in a significant increase in spheroid viability (Figure 2A). Investigation of spheroid morphology showed that E-Cadherin silencing resulted in a complete breakdown of spheroid architecture, with viable cells resting on the bottom of the low attachment well (Figure 2B). Manual reinvestigation of the spheroid volume screen data showed that this had also been observed but had been eliminated from area quantification due to the object being above the set size restrictions. As previously highlighted, BT474 cells overexpress the receptor tyrosine kinase HER2 and harbor an oncogenic mutation in PIK3CA (K111N). We confirmed that silencing of ERBB2 and PIK3CA resulted in reduced spheroid viability, while transfection with non-targeting controls had no effect (Figure 2C).
Next we investigated the impact of siRNA depletion on spheroid histology. BT474 spheroids were reverse transfected with non-targeting control siRNA and siRNAs targeting PIK3CA, ERBB2 and UBB. Silencing of ERBB2 and UBB resulted in a reduction of the pro-proliferative marker Ki67 compared to control siRNA (Figure 2D). The activation of the pro-apoptotic marker cleaved caspase-3 was only observed after UBB silencing, suggesting that depletion of HER2 and PIK3CA did not result in apoptosis but were cytostatic rather than cytotoxic. Indeed, silencing of HER2 and PIK3CA did result in an increase in the protein expression of the cell cycle arrest protein p27 compared to control transfected spheroids.
Taken together, these results show that BT474 cells are driven by oncogenic HER2 and PIK3CA signaling when grown as 3D spheroids. More importantly, these results show that it is possible to design and implement a bespoke siRNA screening library of hundreds of genes in cancer cell line spheroids robustly and reproducibly.
<img alt="Figure 1" src="/files/ftp_upload/54738/54738fig1.jpg" /> 
Figure 1: Cell Line Optimization for 3-dimensional Growth. A. The breast cancer cell lines, MCF10DCIS.com and BT474 were cultured in low attachment plates for 7 days. Brightfield representative images were taken using an inverted microscope. Scale bars = 100 &#181;m. B. MCF10DCIS.com and BT474 spheroids were cultured for 28 days. 100 &#956;L of fresh media was replenished every 3 - 4 days. Spheroids were fixed in 3.8% formaldehyde, embedded, sectioned and stained with hematoxylin and eosin (H&#38;E). Representative images are shown at low and high magnification. Scale bars represent 100 &#181;m and 33 &#181;m, respectively. C. MDA-MB-231 spheroids were cultured for 21 days. 100 &#956;L of fresh media was replenished every 3 - 4 days. Spheroids were fixed in 3.8% formaldehyde, embedded, sectioned and stained with Ki67 and cleaved caspase-3. Representative images are shown. Scale bars = 100 &#181;m. D. BT474, MCF10DCIS.com, MDA-MB-231, and JIMT1 cell lines were reverse transfected with mock (transfection reagent only) and the control siRNAs and UBB, ultra-low attachment plates were then spun to form spheroids. Fresh medium (100 &#181;l) was added on days 1 and 4. After 7 days, cell viability was quantified. Data represent the mean &#177; SD of two independent biological replicates performed in triplicate normalized to control #1. Statistical significance was calculated using an unpaired Students t-test (p&#60; 0.05). E. A flow diagram summarizing the reverse transfection protocol used to functionally interrogate gene dependency in cancer cell line spheroids. <a href="https://cloudflare-jove-com.bdigitaluss.remotexs.co/files/ftp_upload/54738/54738fig1large.jpg" target="_blank">Please click here to view a larger version of this figure.</a>
<img alt="Figure 2" src="/files/ftp_upload/54738/54738fig2.jpg" /> 
Figure 2: Functional Genomic Investigation of BT474 Spheroids Uncovers Oncogenic Dependencies. A. BT474 cells were reverse transfected with the 200-gene human siGENOME siRNA library in triplicate. Spheroid size and viability was observed. Raw data values were plate median normalized and z-scores were calculated to identify significant outliers greater than 1.7x the standard deviation of the plate median 15. Note outlying genes ERBB2, SF3B1, PLK1 and UBB and E-cad. siRNAs that significantly increased or reduced spheroid area and viability are shaded in blue and red, where red depicts the control siRNA&#39;s. B. Cells were reverse transfected with non-targeting control, E-Cadherin (E-Cad), PIK3CA, ERBB2 or UBB siRNA and then spun in an ultra-low attachment plate to form spheroids. After 7 days, brightfield representative spheroid images were taken using an inverted microscope. Scale bars = 100 &#181;m. C. Cells were reverse transfected with non-targeting control, PIK3CA, ERBB2 or UBB siRNA and then spun in an ultra-low attachment plate to form spheroids. After 7 days, cell viability was quantified. Data represent the mean &#177; SD of two independent biological replicates performed in triplicate normalized to control #1. Statistical significance was calculated using an unpaired Students t-test (p &#60; 0.05). D. After 7 days, spheroids were fixed, embedded, sectioned and stained for H&#38;E, Ki67, Cleaved Caspase-3, and p27. Representative images are shown. Scale bars = 100 &#181;m. Note the H&#38;E of the siControl spheroids appear smaller due to an artefact of processing and individual intact spheroids chosen for staining. However this does not detract from the changes observed with the scanned images and cell viability results. <a href="https://cloudflare-jove-com.bdigitaluss.remotexs.co/files/ftp_upload/54738/54738fig2large.jpg" target="_blank">Please click here to view a larger version of this figure.</a>
<table border="1" fo:keep-together.within-page="1" fo:keep-with-next.within-page="always">
	<tbody>
		<tr>
			<td>1</td>
			<td>2</td>
			<td>3</td>
			<td>4</td>
			<td>5</td>
			<td>6</td>
			<td>7</td>
			<td>8</td>
			<td>9</td>
			<td>10</td>
			<td>11</td>
			<td>12</td>
		</tr>
		<tr>
			<td></td>
			<td></td>
			<td></td>
			<td></td>
			<td></td>
			<td></td>
			<td></td>
			<td></td>
			<td></td>
			<td></td>
			<td></td>
			<td></td>
		</tr>
		<tr>
			<td></td>
			<td>Non-targeting 1</td>
			<td>TP53</td>
			<td>DST</td>
			<td>KMT2C</td>
			<td>Untreated 1</td>
			<td>FCGBP</td>
			<td>ARID1B</td>
			<td>FBXM7</td>
			<td>TTC40</td>
			<td>Non-targeting 2</td>
			<td></td>
		</tr>
		<tr>
			<td></td>
			<td>GATA3</td>
			<td>TTN</td>
			<td>MUC12</td>
			<td>MUC4</td>
			<td>AHNAK</td>
			<td>HUWEI1</td>
			<td>DNAH11</td>
			<td>ITPR2</td>
			<td>ABCA13</td>
			<td>CREBBP</td>
			<td></td>
		</tr>
		<tr>
			<td></td>
			<td>MAP2K4</td>
			<td>PIK3CA</td>
			<td>F5</td>
			<td>APOB</td>
			<td>ANKRD30A</td>
			<td>MUC17</td>
			<td>DNAH17</td>
			<td>LAMA2</td>
			<td>ACE</td>
			<td>CSMD2</td>
			<td></td>
		</tr>
		<tr>
			<td></td>
			<td>STARD9</td>
			<td>USH2A</td>
			<td>FAT3</td>
			<td>LPR2</td>
			<td>CSMD3</td>
			<td>MYO18B</td>
			<td>DNAH5</td>
			<td>MDN1</td>
			<td>ARHGAP5</td>
			<td>DNAH9</td>
			<td></td>
		</tr>
		<tr>
			<td></td>
			<td>CXCR3</td>
			<td>MUC16</td>
			<td>RB1</td>
			<td>PKHD1L1</td>
			<td>DNAH2</td>
			<td>SYNE2</td>
			<td>DYNC1H1</td>
			<td>PCLO</td>
			<td>CACNA1B</td>
			<td>ERBB2</td>
			<td></td>
		</tr>
		<tr>
			<td></td>
			<td>PLK1</td>
			<td>SYNE1</td>
			<td>LYST</td>
			<td>PTEN</td>
			<td>SPTA1</td>
			<td>Untreated 2</td>
			<td>VHL</td>
			<td>RYR1</td>
			<td>COL6A3</td>
			<td>UBB</td>
			<td></td>
		</tr>
		<tr>
			<td></td>
			<td></td>
			<td></td>
			<td></td>
			<td></td>
			<td></td>
			<td></td>
			<td></td>
			<td></td>
			<td></td>
			<td></td>
			<td></td>
		</tr>
		<tr>
			<td>1</td>
			<td>2</td>
			<td>3</td>
			<td>4</td>
			<td>5</td>
			<td>6</td>
			<td>7</td>
			<td>8</td>
			<td>9</td>
			<td>10</td>
			<td>11</td>
			<td>12</td>
		</tr>
		<tr>
			<td></td>
			<td></td>
			<td></td>
			<td></td>
			<td></td>
			<td></td>
			<td></td>
			<td></td>
			<td></td>
			<td></td>
			<td></td>
			<td></td>
		</tr>
		<tr>
			<td></td>
			<td>Non-targeting 1</td>
			<td>ENAM</td>
			<td>RYR2</td>
			<td>BRCA2</td>
			<td>Untreated 1</td>
			<td>FMN2</td>
			<td>HECW1</td>
			<td>LAMB4</td>
			<td>SI</td>
			<td>Non-targeting 2</td>
			<td></td>
		</tr>
		<tr>
			<td></td>
			<td>FHOD3</td>
			<td>MACF1</td>
			<td>RYR3</td>
			<td>C2ORF16</td>
			<td>DMD</td>
			<td>FRG1</td>
			<td>HERC2</td>
			<td>MYH11</td>
			<td>STAB1</td>
			<td>ZDBF2</td>
			<td></td>
		</tr>
		<tr>
			<td></td>
			<td>GOLGA6L2</td>
			<td>NEB</td>
			<td>SMG1</td>
			<td>CACNA1E</td>
			<td>DNA14</td>
			<td>GCC2</td>
			<td>HIVEP2</td>
			<td>NIPBL</td>
			<td>TANC1</td>
			<td>ZNF536</td>
			<td></td>
		</tr>
		<tr>
			<td></td>
			<td>HMCN1</td>
			<td>NF1</td>
			<td>UBR5</td>
			<td>CACNA1F</td>
			<td>DYNC2H1</td>
			<td>GON4L</td>
			<td>HYDIN</td>
			<td>PKD1L1</td>
			<td>TF</td>
			<td>ANK3</td>
			<td></td>
		</tr>
		<tr>
			<td></td>
			<td>HRNR</td>
			<td>OBSCN</td>
			<td>USP34</td>
			<td>CYMA5</td>
			<td>FAM208B</td>
			<td>GPR112</td>
			<td>ITSN2</td>
			<td>RNF213</td>
			<td>TPR</td>
			<td>ASPM</td>
			<td></td>
		</tr>
		<tr>
			<td></td>
			<td>PLK1</td>
			<td>PCDH15</td>
			<td>XIRP2</td>
			<td>COL7A1</td>
			<td>FLG2</td>
			<td>Untreated 2</td>
			<td>VHL</td>
			<td>SAGE1</td>
			<td>UNC80</td>
			<td>UBB</td>
			<td></td>
		</tr>
		<tr>
			<td></td>
			<td></td>
			<td></td>
			<td></td>
			<td></td>
			<td></td>
			<td></td>
			<td></td>
			<td></td>
			<td></td>
			<td></td>
			<td></td>
		</tr>
		<tr>
			<td>1</td>
			<td>2</td>
			<td>3</td>
			<td>4</td>
			<td>5</td>
			<td>6</td>
			<td>7</td>
			<td>8</td>
			<td>9</td>
			<td>10</td>
			<td>11</td>
			<td>12</td>
		</tr>
		<tr>
			<td></td>
			<td></td>
			<td></td>
			<td></td>
			<td></td>
			<td></td>
			<td></td>
			<td></td>
			<td></td>
			<td></td>
			<td></td>
			<td></td>
		</tr>
		<tr>
			<td></td>
			<td>Non-targeting 1</td>
			<td>DCHS2</td>
			<td>MUC5B</td>
			<td>ZFHX4</td>
			<td>Untreated 1</td>
			<td>MYO9A</td>
			<td>SPHKAP</td>
			<td>CXORF22</td>
			<td>NCOR1</td>
			<td>VPS13D</td>
			<td></td>
		</tr>
		<tr>
			<td></td>
			<td>ATR</td>
			<td>DMXL2</td>
			<td>MXRA5</td>
			<td>ANK2</td>
			<td>KIAA1210</td>
			<td>PRUNE2</td>
			<td>TCHH</td>
			<td>DANH6</td>
			<td>NOTCH2</td>
			<td>ANKRD12</td>
			<td></td>
		</tr>
		<tr>
			<td></td>
			<td>BIRC6</td>
			<td>DNAH10</td>
			<td>TENM1</td>
			<td>ATM</td>
			<td>LRP1</td>
			<td>SCN10A</td>
			<td>VPS13C</td>
			<td>DNAH7</td>
			<td>SPEN</td>
			<td>C5ORF42</td>
			<td></td>
		</tr>
		<tr>
			<td></td>
			<td>CDH1</td>
			<td>DNAH3</td>
			<td>PEG3</td>
			<td>DIDO1</td>
			<td>MAP1A</td>
			<td>SCN2A</td>
			<td>IPTR3</td>
			<td>ERBB3</td>
			<td>SRRM2</td>
			<td>CCDC88A</td>
			<td></td>
		</tr>
		<tr>
			<td></td>
			<td>CUBN</td>
			<td>NOCK11</td>
			<td>RELN</td>
			<td>DNAH8</td>
			<td>MED12</td>
			<td>SHROOM2</td>
			<td>CEP350</td>
			<td>FAT4</td>
			<td>SZT2</td>
			<td>CHD4</td>
			<td></td>
		</tr>
		<tr>
			<td></td>
			<td>PLK1</td>
			<td>EYS</td>
			<td>SACS</td>
			<td>KIAA1109</td>
			<td>MED13</td>
			<td>Untreated 2</td>
			<td>VHL</td>
			<td>KMT2A</td>
			<td>VPS13A</td>
			<td>UBB</td>
			<td></td>
		</tr>
		<tr>
			<td></td>
			<td></td>
			<td></td>
			<td></td>
			<td></td>
			<td></td>
			<td></td>
			<td></td>
			<td></td>
			<td></td>
			<td></td>
			<td></td>
		</tr>
		<tr>
			<td>1</td>
			<td>2</td>
			<td>3</td>
			<td>4</td>
			<td>5</td>
			<td>6</td>
			<td>7</td>
			<td>8</td>
			<td>9</td>
			<td>10</td>
			<td>11</td>
			<td>12</td>
		</tr>
		<tr>
			<td></td>
			<td></td>
			<td></td>
			<td></td>
			<td></td>
			<td></td>
			<td></td>
			<td></td>
			<td></td>
			<td></td>
			<td></td>
			<td></td>
		</tr>
		<tr>
			<td></td>
			<td>Non-targeting</td>
			<td>QSER1</td>
			<td>ARID1A</td>
			<td>WDFY3</td>
			<td>Untreated 1</td>
			<td>SDK1</td>
			<td>TEX15</td>
			<td>LAMA1</td>
			<td></td>
			<td>Non-targeting 2</td>
			<td></td>
		</tr>
		<tr>
			<td></td>
			<td>COL14A1</td>
			<td>SHROOM3</td>
			<td>ATRX</td>
			<td>EFCAB5</td>
			<td>SF3B1</td>
			<td>CBFB</td>
			<td>AHNAK2</td>
			<td></td>
			<td></td>
			<td></td>
			<td></td>
		</tr>
		<tr>
			<td></td>
			<td>CSMD1</td>
			<td>TBX3</td>
			<td>KIAA0947</td>
			<td>FOXA1</td>
			<td>ITPR1</td>
			<td>DDX3X</td>
			<td>KIF4A</td>
			<td></td>
			<td></td>
			<td></td>
			<td></td>
		</tr>
		<tr>
			<td></td>
			<td>MEFV</td>
			<td>UBR4</td>
			<td>MYCBP2</td>
			<td>INPPL1</td>
			<td>FLG</td>
			<td>HECTD4</td>
			<td>FAT2</td>
			<td></td>
			<td></td>
			<td></td>
			<td></td>
		</tr>
		<tr>
			<td></td>
			<td>MGAM</td>
			<td>VCAN</td>
			<td>NBEAL1</td>
			<td>MAP3K1</td>
			<td>AKAP9</td>
			<td>GPR98</td>
			<td>FOXO3</td>
			<td></td>
			<td></td>
			<td></td>
			<td></td>
		</tr>
		<tr>
			<td></td>
			<td>PLK1</td>
			<td>ZNF462</td>
			<td>SETX</td>
			<td>NRP1</td>
			<td>HERC1</td>
			<td>Untreated 2</td>
			<td>VHL</td>
			<td></td>
			<td></td>
			<td>UBB</td>
			<td></td>
		</tr>
		<tr>
			<td></td>
			<td></td>
			<td></td>
			<td></td>
			<td></td>
			<td></td>
			<td></td>
			<td></td>
			<td></td>
			<td></td>
			<td></td>
			<td></td>
		</tr>
	</tbody>
</table>
Table 1: Plate Layout and Human siRNA Library De-convolution. The table contains the content of each of the siRNA pools and layout for the low attachment plates used in the screen.

Watch this Scientific Journal Video about Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures at JoVE.com

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

Identifying novel drug targets that transition from pre-clinical testing to human trials is a scientific priority. To that end, here we describe a functional genomics approach for examining the impact of gene depletion on cancer cell line spheroids, which more appropriately model human cancers in vivo.

The identification of functional driver events in cancer is central to furthering our understanding of cancer biology and indispensable for the discovery ...

utilizing-functional-genomics-screening-to-identify-potentially-novel

Nanyang Technological University

Research

JoVE Journal

Cancer Research

11.3K Views.  The Institute of Cancer Research. Identifying novel drug targets that transition from pre-clinical testing to human trials is a scientific priority. To that end, here we describe a functional genomics approach for examining the impact of gene depletion on cancer cell line spheroids, which more appropriately model human cancers in vivo.

Video: Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

Preparation and Metabolic Assay of 3-dimensional Spheroid Co-cultures of Pancreatic Cancer Cells and Fibroblasts

Many cancer types, including pancreatic cancer, have a dense fibrotic stroma that plays an important role in tumor progression and invasion. Activated cancer associated fibroblasts are a key component of the tumor stroma that interact with cancer cells and support their growth and survival. Models that recapitulate the interaction of cancer cells and activated fibroblasts are important tools for studying the stromal biology and for development of antitumor agents. Here, a method is described for the rapid generation of robust 3-dimensional (3D) spheroid co-culture of pancreatic cancer cells and activated pancreatic fibroblasts that can be used for subsequent biological studies. Additionally, described is the use of 3D spheroids in carrying out functional metabolic assays to probe cellular bioenergetics pathways using an extracellular flux analyzer paired with a spheroid microplate. Pancreatic cancer cells (Patu8902) and activated pancreatic fibroblast cells (PS1) were co-cultured and magnetized using a biocompatible nanoparticle assembly. Magnetized cells were rapidly bioprinted using magnetic drives in a 96 well format, in growth media to generate spheroids with a diameter ranging between 400-600 &#181;m within 5-7 days of culture. Functional metabolic assays using Patu8902-PS1 spheroids were then carried out using the extracellular flux technology to probe cellular energetic pathways. The method herein is simple, allows consistent generation of cancer cell-fibroblast spheroid co-cultures and can be potentially adapted to other cancer cell types upon optimization of the current described methodology.

Here, a method is described for the preparation of 3-dimensional (3D) spheroid co-culture of pancreatic cancer cells and fibroblasts, followed by measurement of metabolic functions using an extracellular flux analyzer.

Many cancer types, including pancreatic cancer, have a dense fibrotic stroma that plays an important role in tumor progression and invasion. Activated ...

Generation of High-Throughput Three-Dimensional Tumor Spheroids for Drug Screening

Cancer cells have routinely been cultured in two dimensions (2D) on a plastic surface. This technique, however, lacks the true environment a tumor mass is exposed to in vivo. Solid tumors grow not as a sheet attached to plastic, but instead as a collection of clonal cells in a three-dimensional (3D) space interacting with their neighbors, and with distinct spatial properties such as the disruption of normal cellular polarity. These interactions cause 3D-cultured cells to acquire morphological and cellular characteristics which are more relevant to in vivo tumors. Additionally, a tumor mass is in direct contact with other cell types such as stromal and immune cells, as well as the extracellular matrix from all other cell types. The matrix deposited is comprised of macromolecules such as collagen and fibronectin.
In an attempt to increase the translation of research findings in oncology from bench to bedside, many groups have started to investigate the use of 3D model systems in their drug development strategies. These systems are thought to be more physiologically relevant because they attempt to recapitulate the complex and heterogeneous environment of a tumor. These systems, however, can be quite complex, and, although amenable to growth in 96-well formats, and some now even in 384, they offer few choices for large-scale growth and screening. This observed gap has led to the development of the methods described here in detail to culture tumor spheroids in a high-throughput capacity in 1536-well plates. These methods represent a compromise to the highly complex matrix-based systems, which are difficult to screen, and conventional 2D assays. A variety of cancer cell lines harboring different genetic mutations are successfully screened, examining compound efficacy by using a curated library of compounds targeting the Mitogen-Activated Protein Kinase or MAPK pathway. The spheroid culture responses are then compared to the response of cells grown in 2D, and differential activities are reported. These methods provide a unique protocol for testing compound activity in a high-throughput 3D setting.

Across a wide variety of disease indications, more physiologically relevant models are being developed and implemented into drug discovery programs. The new model system described here demonstrates how three-dimensional tumor spheroids can be cultured and screened in a high-throughput 1536-well plate-based system to search for new oncology drugs.

Cancer cells have routinely been cultured in two dimensions (2D) on a plastic surface. This technique, however, lacks the true environment a tumor mass is ...

Physiologic Patient Derived 3D Spheroids for Anti-neoplastic Drug Screening to Target Cancer Stem Cells

In this protocol, we outline the procedure for generation of tumor spheroids within 384-well hanging droplets to allow for high-throughput screening of anti-cancer therapeutics in a physiologically representative microenvironment. We outline the formation of patient derived cancer stem cell spheroids, as well as, the manipulation of these spheroids for thorough analysis following drug treatment. Specifically, we describe collection of spheroid morphology, proliferation, viability, drug toxicity, cell phenotype and cell localization data. This protocol focuses heavily on analysis techniques that are easily implemented using the 384-well hanging drop platform, making it ideal for high throughput drug screening. While we emphasize the importance of this model in ovarian cancer studies and cancer stem cell research, the 384-well platform is amenable to research of other cancer types and disease models, extending the utility of the platform to many fields. By improving the speed of personalized drug screening and the quality of screening results through easily implemented physiologically representative 3D cultures, this platform is predicted to aid in the development of new therapeutics and patient-specific treatment strategies, and thus have wide-reaching clinical impact.

This protocol describes generation of patient-derived spheroids, and downstream analysis including quantification of proliferation, cytotoxicity testing, flow cytometry, immunofluorescence staining and confocal imaging, in order to assess drug candidates&#8217; potential as anti-neoplastic therapeutics. This protocol supports precision medicine with identification of specific drugs for each patient and stage of disease.

In this protocol, we outline the procedure for generation of tumor spheroids within 384-well hanging droplets to allow for high-throughput screening of ...

Assessing Cell Viability and Death in 3D Spheroid Cultures of Cancer Cells

Three-dimensional spheroids of cancer cells are important tools for both cancer drug screens and for gaining mechanistic insight into cancer cell biology. The power of this preparation lies in its ability to mimic many aspects of the in vivo conditions of tumors while being fast, cheap, and versatile enough to allow relatively high-throughput screening. The spheroid culture conditions can recapitulate the physico-chemical gradients in a tumor, including the increasing extracellular acidity, increased lactate, and decreasing glucose and oxygen availability, from the spheroid periphery to its core. Also, the mechanical properties and cell-cell interactions of in vivo tumors are in part mimicked by this model. The specific properties and consequently the optimal growth conditions, of 3D spheroids, differ widely between different types of cancer cells. Furthermore, the assessment of cell viability and death in 3D spheroids requires methods that differ in part from those employed for 2D cultures. Here we describe several protocols for preparing 3D spheroids of cancer cells, and for using such cultures to assess cell viability and death in the context of evaluating the efficacy of anticancer drugs.

Here, we present several simple methods for evaluating viability and death in 3D cancer cell spheroids, which mimic the physico-chemical gradients of in vivo tumors much better than the 2D culture. The spheroid model, therefore, allows evaluation of the cancer drug efficacy with improved translation to in vivo conditions.

Three-dimensional spheroids of cancer cells are important tools for both cancer drug screens and for gaining mechanistic insight into cancer cell biology. ...

Robotic Production of Cancer Cell Spheroids with an Aqueous Two-phase System for Drug Testing

Cancer cell spheroids present a relevant in vitro model of avascular tumors for anti-cancer drug testing applications. A detailed protocol for producing both mono-culture and co-culture spheroids in a high throughput 96-well plate format is described in this work. This approach utilizes an aqueous two-phase system to confine cells into a drop of the denser aqueous phase immersed within the second aqueous phase. The drop rests on the well surface and keeps cells in close proximity to form a single spheroid. This technology has been adapted to a robotic liquid handler to produce size-controlled spheroids and expedite the process of spheroid production for compound screening applications. Spheroids treated with a clinically-used drug show reduced cell viability with increase in the drug dose. The use of a standard micro-well plate for spheroid generation makes it straightforward to analyze viability of cancer cells of drug-treated spheroids with a micro-plate reader. This technology is straightforward to implement both robotically and with other liquid handling tools such as manual pipettes.

A protocol for robotic printing of cancer cell spheroids in a high throughput 96-well plate format using an aqueous two-phase system is presented.

Cancer cell spheroids present a relevant in vitro model of avascular tumors for anti-cancer drug testing applications. A detailed protocol for producing ...

Bioengineering

Establishing 3-Dimensional Spheroids from Patient-Derived Tumor Samples and Evaluating their Sensitivity to Drugs

Despite remarkable advances in understanding tumor biology, the vast majority of oncology drug candidates entering clinical trials fail, often due to a lack of clinical efficacy. This high failure rate illuminates the inability of the current preclinical models to predict clinical efficacy, mainly due to their inadequacy in reflecting tumor heterogeneity and the tumor microenvironment. These limitations can be addressed with 3-dimensional (3D) culture models (spheroids) established from human tumor samples derived from individual patients. These 3D cultures represent real-world biology better than established cell lines that do not reflect tumor heterogeneity. Furthermore, 3D cultures are better than 2-dimensional (2D) culture models (monolayer structures) since they replicate elements of the tumor environment, such as hypoxia, necrosis, and cell adhesion, and preserve the natural cell shape and growth. In the present study, a method was developed for preparing primary cultures of cancer cells from individual patients that are 3D and grow in multicellular spheroids. The cells can be derived directly from patient tumors or patient-derived xenografts. The method is widely applicable to solid tumors (e.g., colon, breast, and lung) and is also cost-effective, as it can be performed in its entirety in a typical cancer research/cell biology lab without relying on specialized equipment. Herein, a protocol is presented for generating 3D tumor culture models (multicellular spheroids) from primary cancer cells and evaluating their sensitivity to drugs using two complementary approaches: a cell-viability assay (MTT) and microscopic examinations. These multicellular spheroids can be used to assess potential drug candidates, identify potential biomarkers or therapeutic targets, and investigate the mechanisms of response and resistance.

The present protocol describes generating 3D tumor culture models from primary cancer cells and evaluating their sensitivity to drugs using cell-viability assays and microscopic examinations.

Despite remarkable advances in understanding tumor biology, the vast majority of oncology drug candidates entering clinical trials fail, often due to a ...

Generation of 3D Tumor Spheroids for Drug Evaluation Studies

In recent decades, in addition to monolayer-cultured cells, three-dimensional tumor spheroids have been developed as a potentially powerful tool for the evaluation of anticancer drugs. However, the conventional culture methods lack the ability to manipulate the tumor spheroids in a homogeneous manner at the three-dimensional level. To address this limitation, in this paper, we present a convenient and effective method of constructing average-sized tumor spheroids. Additionally, we describe a method of image-based analysis using artificial intelligence-based analysis software that can scan the whole plate and obtain data on three-dimensional spheroids. Several parameters were studied. By using a standard method of tumor spheroid construction and a high-throughput imaging and analysis system, the effectiveness and accuracy of drug tests performed on three-dimensional spheroids can be dramatically increased.

This article demonstrates a standardized method for constructing three-dimensional tumor spheroids. A strategy for spheroid observation and image-based deep-learning analysis using an automated imaging system is also described.

In recent decades, in addition to monolayer-cultured cells, three-dimensional tumor spheroids have been developed as a potentially powerful tool for the ...

Genome-Scale Screening to Identify and Compare Therapeutic Targets in Tumors

Genetic Profiling and Genome-Scale Dropout Screening to Identify Therapeutic Targets in Mouse Models of Malignant Peripheral Nerve Sheath Tumor

Malignant Peripheral Nerve Sheath Tumors (MPNSTs) are derived from Schwann cells or their precursors. In patients with the tumor susceptibility syndrome neurofibromatosis type 1 (NF1), MPNSTs are the most common malignancy and the leading cause of death. These rare and aggressive soft-tissue sarcomas offer a stark future, with 5-year disease-free survival rates of 34-60%. Treatment options for individuals with MPNSTs are disappointingly limited, with disfiguring surgery being the foremost treatment option. Many once-promising therapies such as tipifarnib, an inhibitor of Ras signaling, have failed clinically. Likewise, phase II clinical trials with erlotinib, which targets the epidermal growth factor (EFGR), and sorafenib, which targets the vascular endothelial growth factor receptor (VEGF), platelet-derived growth factor receptor (PDGF), and Raf, in combination with standard chemotherapy, have also failed to produce a response in patients. 
In recent years, functional genomic screening methods combined with genetic profiling of cancer cell lines have proven useful for identifying essential cytoplasmic signaling pathways and the development of target-specific therapies. In the case of rare tumor types, a variation of this approach known as cross-species comparative oncogenomics is increasingly being used to identify novel therapeutic targets. In cross-species comparative oncogenomics, genetic profiling and functional genomics are performed in genetically engineered mouse (GEM) models and the results are then validated in the rare human specimens and cell lines that are available. 
This paper describes how to identify candidate driver gene mutations in human and mouse MPNST cells using whole exome sequencing (WES). We then describe how to perform genome-scale shRNA screens to identify and compare critical signaling pathways in mouse and human MPNST cells and identify druggable targets in these pathways. These methodologies provide an effective approach to identifying new therapeutic targets in a variety of human cancer types.

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens 

We have developed a cross-species comparative oncogenomics approach utilizing genomic analyses and functional genomic screens to identify and compare therapeutic targets in tumors arising in genetically engineered mouse models and the corresponding human tumor type.

Malignant Peripheral Nerve Sheath Tumors (MPNSTs) are derived from Schwann cells or their precursors. In patients with the tumor susceptibility syndrome ...

Spheroid Drug Sensitivity Screening in Glioma Stem Cell Lines

In vitro drug sensitivity screens are important tools in the discovery of anti-cancer drug combination therapies. Typically, these in vitro drug screens are performed on cells grown in a monolayer. However, these two-dimensional (2D) models are considered less accurate compared to three-dimensional (3D) spheroid cell models; this is especially true for glioma stem cell lines. Cells grown in spheres activate different signaling pathways and are considered more representative of in vivo models than monolayer cell lines. This protocol describes a method for in vitro drug screening of spheroid lines; mouse and human glioma stem cell lines are used as an example. This protocol describes a 3D spheroid drug sensitivity and synergy assay that can be used to determine if a drug or drug combination induces cell death and if two drugs synergize. Glioma stem cell lines are&#160;modified to express RFP. Cells are plated in low attachment round well bottom 96 plates, and spheres are allowed to form overnight. Drugs are added, and the growth is monitored by measuring the RFP signal over time using the Incucyte live imaging system,&#160;a fluorescence microscope embedded in the tissue culture incubator. Half maximal inhibitory concentration (IC50), median lethal dose (LD50), and synergy score are subsequently calculated to evaluate sensitivities to drugs alone or in combination. The three-dimensional nature of this assay&#160;provides a more accurate reflection of tumor growth, behavior, and drug sensitivities in vivo, thus forming the basis for further preclinical investigation.

In vitro drug sensitivity screens are important tools for discovering anti-cancer drug combinations. Cells grown in spheres activate different signaling pathways and are considered more representative of in vivo models than monolayer cell lines. This protocol describes a method for in vitro drug screening for spheroid lines.

In vitro drug sensitivity screens are important tools in the discovery of anti-cancer drug combination therapies. Typically, these in vitro drug screens ...

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Monoclonal antibody-based immunotherapy targeting tumor antigens is now a mainstay of cancer treatment. One of the clinically relevant mechanisms of action of the antibodies is antibody-dependent cellular cytotoxicity (ADCC), where the antibody binds to the cancer cells and engages the cellular component of the immune system, e.g., natural killer (NK) cells, to kill the tumor cells. The effectiveness of these therapies could be improved by identifying adjuvant compounds that increase the sensitivity of the cancer cells or the potency of the immune cells. In addition, undiscovered drug interactions in cancer patients co-medicated for previous conditions or cancer-associated symptoms may determine the success of the antibody therapy; therefore, such unwanted drug interactions need to be eliminated. With these goals in mind, we created a cancer ADCC model and describe here a simple protocol to find ADCC-modulating drugs. Since 3D models such as cancer cell spheroids are superior to 2D cultures in predicting in vivo responses of tumors to anticancer therapies, spheroid co-cultures of EGFP-expressing HER2+ JIMT-1 breast cancer cells and the NK92.CD16 cell lines were set up and induced with Trastuzumab, a monoclonal antibody clinically approved against HER2-positive breast cancer. JIMT-1 spheroids were allowed to form in cell-repellent U-bottom 96-well plates. On day 3, NK cells and Trastuzumab were added. The spheroids were then stained with Annexin V-Alexa 647 to measure apoptotic cell death, which was quantitated in the peripheral zone of the spheroids with an automated microscope. The applicability of our assay to identify ADCC-modulating molecules is demonstrated by showing that Sunitinib, a receptor tyrosine kinase inhibitor approved by the FDA against metastatic cancer, almost completely abolishes ADCC. The generation of the spheroids and image acquisition and analysis pipelines are compatible with high-throughput screening for ADCC-modulating compounds in cancer cell spheroids.

Here, we present a method to identify compounds that modulate the ADCC mechanism, an important cancer cell-killing mechanism of antitumor antibodies. The cytotoxic effect of NK cells is measured in breast cancer cell spheroids in the presence of Trastuzumab. Image analysis identifies live and dead killer and target cells in spheroids.

Monoclonal antibody-based immunotherapy targeting tumor antigens is now a mainstay of cancer treatment. One of the clinically relevant mechanisms of ...